Prelude Therapeutics Inc logo

Prelude Therapeutics Inc

$ 7.20 +0.06 (+0.84%) 04:00 PM EST
P/E:
At Loss
P/B:
1.59
Market Cap:
$ 344.50M
Enterprise V:
$ 118.97M
Volume:
108.04K
Avg Vol (2M):
94.89K
Volume:
108.04K
Market Cap $:
344.50M
PE Ratio:
At Loss
Avg Vol (2-Month):
94.89K
Enterprise Value $:
118.97M
PB Ratio:
1.59

Business Description

Description
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
Name Current Vs Industry Vs History
Cash-To-Debt 161.41
Equity-to-Asset 0.9
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -74.4
3-Year EPS without NRI Growth Rate -74.5
3-Year FCF Growth Rate -64.3

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 66.69
9-Day RSI 63.29
14-Day RSI 60.85
6-1 Month Momentum % -25.28
12-1 Month Momentum % -53.15

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.52
Quick Ratio 10.52
Cash Ratio 10.39

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -14
Name Current Vs Industry Vs History
ROE % -45.41
ROA % -42.17
ROIC % -753.43
ROC (Joel Greenblatt) % -2063.48
ROCE % -46.44

Financials (Next Earnings Date:2023-03-16 Est.)

PRLD's 30-Y Financials

How Prelude Therapeutics Inc (PRLD) Makes Its Money

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:PRLD

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Executives

Details

Valuation chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -2.55
Beta 0
Volatility % 69.96
14-Day RSI 60.85
14-Day ATR ($) 0.561235
20-Day SMA ($) 6.491
12-1 Month Momentum % -53.15
52-Week Range ($) 3.87 - 10.72
Shares Outstanding (Mil) 47.86

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Prelude Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Prelude Therapeutics Inc Stock Events

Event Date Price($) Daily Change %
No Event Data

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1